Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2025-06-18 00:00:00 ET · period of report 2025-06-16 · accession 0000950170-25-087937 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-06-18 | 2025-06-16 | NAMS | Kling Douglas F | COO | M - OptEx | $10.20 | +100.0K | 122.1K | +452% | +$1.02M |
| DMT | 2025-06-18 | 2025-06-16 | NAMS | Kling Douglas F | COO | S - Sale+OE | $19.29 | -100.0K | 62.1K | -62% | -$1.93M |
| DMT | 2025-06-18 | 2025-06-16 | NAMS | Kling Douglas F | COO | M - OptEx | $0.00 | -100.0K | 372.8K | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-06-16 | M | A | 21,899 | $10.90 | 144,000 | D | — | — | |
| 2 | Common | Ordinary Shares | 2025-06-16 | M | A | 78,101 | $10.00 | 122,101 | D | — | — | |
| 3 | Common | Ordinary Shares | 2025-06-16 | S | D | 18,109 | $19.75 | 44,000 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.60 per share to $20.21 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 4 | Common | Ordinary Shares | 2025-06-16 | S | D | 81,891 | $19.19 | 62,109 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.60 per share to $19.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 5 | Derivative | Option (right to buy) | 2025-06-16 | M | D | 21,899 | $0.00 | 261,314 | D | $10.90 · — to 2033-01-01 | 21,899 Ordinary Shares | (F5) The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| 6 | Derivative | Option (right to buy) | 2025-06-16 | M | D | 78,101 | $0.00 | 372,829 | D | $10.00 · — to 2032-11-22 | 78,101 Ordinary Shares | (F4) The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. |